SPERO THERAPEUTICS INC (SPRO) Stock Price & Overview
NASDAQ:SPRO • US84833T1034
Current stock price
The current stock price of SPRO is 2.49 USD. Today SPRO is up by 2.47%. In the past month the price increased by 6.11%. In the past year, price increased by 317.53%.
SPRO Key Statistics
- Market Cap
- 140.287M
- P/E
- 20.75
- Fwd P/E
- 3.64
- EPS (TTM)
- 0.12
- Dividend Yield
- N/A
SPRO Stock Performance
SPRO Stock Chart
SPRO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SPRO. When comparing the yearly performance of all stocks, SPRO is one of the better performing stocks in the market, outperforming 97.9% of all stocks.
SPRO Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to SPRO. SPRO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
SPRO Earnings
On March 26, 2026 SPRO reported an EPS of 0.53 and a revenue of 41.30M. The company beat EPS expectations (359.8% surprise).
SPRO Forecast & Estimates
6 analysts have analysed SPRO and the average price target is 4.08 USD. This implies a price increase of 63.86% is expected in the next year compared to the current price of 2.49.
For the next year, analysts expect an EPS growth of 469.5% and a revenue growth -96.86% for SPRO
SPRO Groups
Sector & Classification
SPRO Financial Highlights
Over the last trailing twelve months SPRO reported a non-GAAP Earnings per Share(EPS) of 0.12. The EPS increased by 109.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.83% | ||
| ROA | 12.44% | ||
| ROE | 14.52% | ||
| Debt/Equity | 0 |
SPRO Ownership
SPRO Latest News, Press Relases and Analysis
SPRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.86 | 369.265B | ||
| AMGN | AMGEN INC | 14.98 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.8 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.53 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.26 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.31 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.58 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.58 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.44 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SPRO
Company Profile
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Company Info
IPO: 2017-11-02
SPERO THERAPEUTICS INC
675 Massachusetts Ave Ste 14
Cambridge MASSACHUSETTS 02139 US
CEO: Ankit Mahadevia
Employees: 32
Phone: 18572421600
SPERO THERAPEUTICS INC / SPRO FAQ
What does SPERO THERAPEUTICS INC do?
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Can you provide the latest stock price for SPERO THERAPEUTICS INC?
The current stock price of SPRO is 2.49 USD. The price increased by 2.47% in the last trading session.
Does SPERO THERAPEUTICS INC pay dividends?
SPRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of SPRO stock?
SPRO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is SPERO THERAPEUTICS INC (SPRO) expected to grow?
The Revenue of SPERO THERAPEUTICS INC (SPRO) is expected to decline by -96.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for SPERO THERAPEUTICS INC?
SPERO THERAPEUTICS INC (SPRO) currently has 32 employees.
What is the market capitalization of SPRO stock?
SPERO THERAPEUTICS INC (SPRO) has a market capitalization of 140.29M USD. This makes SPRO a Micro Cap stock.